5PSQ-083 Study of the prevalence of immunogenicity in patients treated with anti-tumour necrosis factor monoclonal antibodies

BACKGROUND: The loss of response in patients treated with anti-TNFα monoclonal antibodies is relatively frequent. One of the reasons is the development of immunogenicity, causing treatment failure. PURPOSE: To determine the prevalence of immunogenicity in patients with anti-TNF monoclonal antibodies...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Hosp Pharm
Autori principali: Candel, M Gil, Navalón, C Iniesta, Candela, M Onteniente, Redondo, L Rentero, Requejo, C Caballero, Valverde, N Salar, Muñoz, C Gallego
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Group 2018
Soggetti:
Section 5: Patient safety and quality assurance
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535275/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.437
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi